Company news

Gossamer Bio, Inc. news in 2026

Gossamer Bio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

September 23, 2026

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

September 16, 2026

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

September 11, 2026

Gossamer Bio Announces 1-for-80 Reverse Stock Split

September 9, 2026

Gossamer Bio to Present at Cantor Global Healthcare Conference

September 4, 2026

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

August 21, 2026

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

July 27, 2026

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

July 1, 2026

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

June 17, 2026

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

June 3, 2026

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

June 1, 2026

GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS

May 26, 2026

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

May 18, 2026

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026

Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

May 15, 2026

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

March 16, 2026

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

February 22, 2026

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2026

Calls in 2026

Decks in 2026